{
  "id": 16302572,
  "title": "BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026",
  "url": "https://urgent.news/2026/10/24/beone-presents-compelling-data-in-hard-to-treat-liver-and-lung",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-24T08:18:22.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/beone-presents-compelling-data-in-hard-to-treat-liver-and-lung-cancers-at-esmo-2026"
  },
  "original_language": "en",
  "account": null,
  "summary": "Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancer Brain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient dataset First clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}